Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

Adagene (Nasdaq: ADAG) announced that muzastotug (ADG126), a masked anti-CTLA-4 antibody, will be highlighted in two poster presentations at the AACR Annual Meeting in San Diego, April 17-22, 2026.

Rhea-AI Summary

Adagene (Nasdaq: ADAG) announced that muzastotug (ADG126), a masked anti-CTLA-4 antibody, will be highlighted in two poster presentations at the AACR Annual Meeting in San Diego, April 17-22, 2026.

Presentations are scheduled April 20, 2026 at 9:00 AM PT in Poster Sections 50 and 51 (Poster Board 14), covering a Ph1b evaluation in MSS colorectal cancer and phase 1b/2 Morpheus Liver study results in unresectable or metastatic HCC.

Argus Mar 18 session

+0.77% close to close Open Argus

Details

News Market Reaction – ADAG

On Mar 18, the first trading day after this news, ADAG closed 0.77% above the previous close.

Data tracked by StockTitan Argus for the Mar 18 session.

Key Figures

AACR 2026 dates: April 17–22, 2026 Session time: April 20, 2026, 9:00 AM–12:00 PM Poster section (CRC study): Section 51, Board 14 +5 more

AACR 2026 dates

April 17–22, 2026

AACR Annual Meeting schedule in San Diego

Session time

April 20, 2026, 9:00 AM–12:00 PM

Poster sessions for muzastotug presentations

Poster section (CRC study)

Section 51, Board 14

Phase 1b MSS colorectal cancer combination study

Poster section (HCC study)

Section 50, Board 14

Morpheus Liver hepatocellular carcinoma study

Abstract number (CRC)

CT083

ADG126+pembrolizumab+fruquintinib MSS colorectal cancer abstract

Abstract number (HCC)

CT054

Morpheus Liver muzastotug combination arm abstract

Current price

$3.91

Pre-news trading level vs 52-week high $4.5791

Price change 24h

-3.39%

Move ahead of AACR poster announcement

Historical Context

5 past events · Latest: Feb 17

5 events

1. Feb 17

   Investor conferences

   24h Move

   +1.2%

   Planned participation in two healthcare investor conferences with webcasts.

2. Jan 23

   Business update

   24h Move

   +22.7%

   Cash position of $74.5M and 2026 objectives focused on muzastotug.

3. Dec 16

   Fast Track status

   24h Move

   +13.8%

   FDA Fast Track designation for muzastotug plus pembrolizumab in MSS CRC.

4. Nov 13

   Licensing deal

   24h Move

   +1.7%

   Licensing agreement with Third Arc Bio for two masked CD3 T cell engagers.

5. Oct 31

   Clinical milestone

   24h Move

   -7.3%

   First patient dosed in randomized Phase 2 dose-optimization study of muzastotug.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

microsatellite stable colorectal cancer, hepatocellular carcinoma, phase 1b/2, anti-ctla-4, +2 more

6 terms

microsatellite stable colorectal cancer medical

"in advanced and metastatic microsatellite stable colorectal cancer"

Microsatellite stable colorectal cancer is a form of colon or rectal cancer whose short, repeating DNA sequences (microsatellites) remain unchanged, indicating a low level of random mutations. That stability matters to investors because it influences how well certain therapies, especially immune-based drugs, are likely to work, shapes clinical trial design and market opportunity, and affects the valuation and risk profile of companies developing treatments for this patient group.

hepatocellular carcinoma medical

"patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC)"

Hepatocellular carcinoma is the most common form of primary liver cancer, arising from the main functional cells of the liver. For investors it matters because its serious health impact drives demand for diagnostic tests, treatments and long-term care; progress in trials or approvals can change a drugmaker’s revenue outlook much like a successful product launch can reshape a company’s future.

phase 1b/2 medical

"Results from the phase 1b/2 Morpheus Liver study in patients"

Phase 1b/2 is a combined early-stage human study that first checks a drug’s safety and side effects in a small group and then expands to test whether it shows signs of working in patients. Think of it as a product test that first confirms it’s safe to use, then looks for early evidence of benefit; positive results can significantly reduce clinical risk and increase a company’s value, while negative results raise the opposite.

anti-ctla-4 medical

"muzastotug, an anti-CTLA-4 masking antibody"

Anti-CTLA-4 is a class of drugs that block the CTLA-4 protein, a natural “brake” on immune cells, allowing the immune system to better recognize and attack cancer cells. For investors, these therapies can represent large commercial opportunity if clinical trials and regulatory approvals succeed, but they also carry significant development, safety and regulatory risks—like releasing a parking brake to boost performance while increasing the chance of losing control.

first-in-human medical

"Session Title: First-in-Human Phase I Clinical Trials"

A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.

poster presentations technical

"muzastotug will be highlighted in two poster presentations"

Poster presentations are visual summaries of research findings displayed at scientific conferences on large boards or electronic screens, often accompanied by a brief in-person explanation. They matter to investors because they reveal early or detailed data about a drug, device, or study outcome before full publication; think of them as a research preview or trade-show demo that can change expectations about a product’s prospects once results are seen and discussed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that muzastotug will be highlighted in two poster presentations at this year’s AACR Meeting, taking place April 17-22 in San Diego, CA.

The following abstracts have been selected for presentation at AACR 2026:

Title: Ph1b evaluation of ADG126 (muzastotug, an anti-CTLA-4 masking antibody) pembrolizumab (Pembro) IO doublet in combination with fruquintinib (Fruq) in advanced and metastatic microsatellite stable colorectal cancer
Session Title: Phase I Clinical Trials in Progress
Session Start: April 20, 2026, 9:00 AM - 12:00 PM Pacific Time
Location: Poster Section 51
Poster Board Number: 14
Abstract Presentation Number: CT083

Title: Results from the phase 1b/2 Morpheus Liver study in patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC): Muzastotug (ADG126: masked anti-CTLA-4 Ab) combination arm
Session Title: First-in-Human Phase I Clinical Trials
Session Start: April 20, 2026, 9:00 AM - 12:00 PM Pacific Time
Location: Poster Section 50
Poster Board Number: 14
Abstract Presentation Number: CT054

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody precision masking technology in multiple approaches at the vanguard of science.

Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene’s lead clinical program, muzastotug (ADG126), is a masked, anti-CTLA-4 SAFEbody with FDA Fast Track designation that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. Muzastotug is currently in Phase 1b/2 and Phase 2 clinical studies in combination with anti-PD-1 therapy, particularly focused on microsatellite stable (MSS) metastatic colorectal cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multi-specific T-cell engagers.

For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and X.

SAFEbody^® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Investor Contacts:

Raymond Tam
raymond_tam@adagene.com

Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Adagene (ADAG) present muzastotug (ADG126) at AACR 2026?

Adagene will present muzastotug on April 20, 2026 during AACR poster sessions. According to the company, both abstracts are scheduled for April 20, 2026, 9:00 AM - 12:00 PM Pacific Time in Poster Sections 50 and 51.

What topics will the ADG126 posters cover at AACR 2026?

The posters cover a Ph1b IO doublet trial in MSS colorectal cancer and the phase 1b/2 Morpheus Liver study in HCC. According to the company, one abstract reports ADG126 with pembrolizumab and fruquintinib; the other reports combination-arm results in unresectable or metastatic HCC.

Where exactly can attendees find Adagene's poster presentations at AACR 2026?

Adagene's posters will be in Poster Sections 50 and 51 at Poster Board Number 14. According to the company, both presentations list Poster Board 14 and will be displayed during the April 20, 2026 poster sessions from 9:00 AM - 12:00 PM PT.

What is muzastotug (ADG126) being evaluated for in the AACR presentations?

Muzastotug is being evaluated as a masked anti-CTLA-4 antibody in combination therapies for solid tumors. According to the company, presentations include a Ph1b study in microsatellite stable colorectal cancer and combination-arm results in hepatocellular carcinoma.

Which clinical trials of ADG126 are reported at AACR 2026?

Two trials are reported: a Phase 1b evaluation in MSS colorectal cancer and the phase 1b/2 Morpheus Liver study in HCC. According to the company, both abstracts were selected for poster presentation at AACR 2026 on April 20.

How can investors and researchers use the ADG126 AACR presentations for due diligence?

The posters provide early clinical data and combination-treatment context for ADG126 that may inform investment and research views. According to the company, the presentations summarize Phase 1b and phase 1b/2 combination-arm results relevant to oncology development programs.